Concepts (179)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Protein Kinase Inhibitors | 9 | 2024 | 26 | 3.540 |
Why?
|
Cryptosporidium parvum | 5 | 2024 | 6 | 3.160 |
Why?
|
Enzyme Inhibitors | 8 | 2025 | 34 | 2.820 |
Why?
|
IMP Dehydrogenase | 10 | 2025 | 10 | 2.650 |
Why?
|
Receptor-Interacting Protein Serine-Threonine Kinase 2 | 5 | 2021 | 6 | 2.330 |
Why?
|
Cryptosporidiosis | 4 | 2024 | 5 | 2.150 |
Why?
|
Aporphines | 3 | 2021 | 3 | 1.810 |
Why?
|
Antineoplastic Agents | 4 | 2021 | 72 | 1.650 |
Why?
|
Protein Kinases | 2 | 2024 | 17 | 1.620 |
Why?
|
Pyridines | 3 | 2021 | 20 | 1.460 |
Why?
|
Receptor-Interacting Protein Serine-Threonine Kinases | 4 | 2024 | 7 | 1.300 |
Why?
|
Cryptosporidium | 3 | 2024 | 4 | 1.230 |
Why?
|
Structure-Activity Relationship | 11 | 2023 | 44 | 1.090 |
Why?
|
Nod2 Signaling Adaptor Protein | 3 | 2021 | 3 | 1.030 |
Why?
|
Humans | 25 | 2024 | 5357 | 1.010 |
Why?
|
Pyrimidinones | 2 | 2024 | 3 | 0.980 |
Why?
|
Signal Transduction | 5 | 2021 | 223 | 0.960 |
Why?
|
Drug Design | 4 | 2021 | 16 | 0.930 |
Why?
|
Antiparasitic Agents | 2 | 2020 | 2 | 0.850 |
Why?
|
Vasodilator Agents | 1 | 2021 | 3 | 0.770 |
Why?
|
Lewis Acids | 1 | 2021 | 1 | 0.770 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2021 | 6 | 0.770 |
Why?
|
Dimerization | 1 | 2021 | 14 | 0.760 |
Why?
|
Molecular Structure | 7 | 2021 | 85 | 0.760 |
Why?
|
Immunosuppressive Agents | 1 | 2021 | 19 | 0.760 |
Why?
|
Anti-Infective Agents | 1 | 2021 | 14 | 0.760 |
Why?
|
Plant Extracts | 1 | 2021 | 19 | 0.750 |
Why?
|
Binding Sites | 7 | 2025 | 69 | 0.750 |
Why?
|
Anilides | 1 | 2020 | 4 | 0.730 |
Why?
|
Nod Signaling Adaptor Proteins | 1 | 2020 | 2 | 0.710 |
Why?
|
Aminopyridines | 1 | 2020 | 6 | 0.710 |
Why?
|
Pyrazoles | 2 | 2018 | 19 | 0.630 |
Why?
|
Phenylurea Compounds | 1 | 2018 | 3 | 0.610 |
Why?
|
Cell Line, Tumor | 7 | 2021 | 172 | 0.580 |
Why?
|
Mycobacterium tuberculosis | 4 | 2022 | 10 | 0.570 |
Why?
|
Drug Discovery | 3 | 2018 | 17 | 0.570 |
Why?
|
Molecular Docking Simulation | 4 | 2021 | 29 | 0.560 |
Why?
|
Crystallography, X-Ray | 5 | 2025 | 38 | 0.550 |
Why?
|
Peptides, Cyclic | 1 | 2016 | 6 | 0.550 |
Why?
|
Sodium-Potassium-Exchanging ATPase | 1 | 2016 | 17 | 0.550 |
Why?
|
Protein Binding | 7 | 2025 | 118 | 0.520 |
Why?
|
Micromonospora | 1 | 2015 | 1 | 0.520 |
Why?
|
Depsipeptides | 1 | 2015 | 2 | 0.520 |
Why?
|
Disulfides | 1 | 2015 | 6 | 0.520 |
Why?
|
Acetanilides | 1 | 2014 | 1 | 0.490 |
Why?
|
Coumarins | 1 | 2014 | 2 | 0.490 |
Why?
|
Animals | 11 | 2024 | 1798 | 0.470 |
Why?
|
Neoplasms | 3 | 2021 | 98 | 0.450 |
Why?
|
Stereoisomerism | 3 | 2021 | 21 | 0.450 |
Why?
|
Central Nervous System | 1 | 2012 | 8 | 0.410 |
Why?
|
Neurodegenerative Diseases | 1 | 2012 | 13 | 0.410 |
Why?
|
Benzoxazoles | 4 | 2022 | 4 | 0.410 |
Why?
|
Mice | 7 | 2024 | 716 | 0.400 |
Why?
|
Sulfones | 2 | 2021 | 10 | 0.380 |
Why?
|
Fluorescent Dyes | 2 | 2021 | 32 | 0.370 |
Why?
|
Models, Molecular | 5 | 2025 | 84 | 0.360 |
Why?
|
Antitubercular Agents | 3 | 2022 | 5 | 0.340 |
Why?
|
Isomerism | 2 | 2021 | 6 | 0.320 |
Why?
|
Cell Proliferation | 3 | 2021 | 120 | 0.300 |
Why?
|
Molecular Targeted Therapy | 3 | 2021 | 36 | 0.280 |
Why?
|
Disease Models, Animal | 3 | 2024 | 242 | 0.270 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2016 | 53 | 0.260 |
Why?
|
Catalytic Domain | 1 | 2025 | 13 | 0.250 |
Why?
|
Antiprotozoal Agents | 1 | 2024 | 3 | 0.240 |
Why?
|
Protozoan Proteins | 1 | 2024 | 4 | 0.240 |
Why?
|
Inhibitory Concentration 50 | 1 | 2024 | 7 | 0.240 |
Why?
|
Cyclooxygenase 2 | 2 | 2021 | 7 | 0.240 |
Why?
|
Caco-2 Cells | 1 | 2024 | 17 | 0.240 |
Why?
|
Lactones | 2 | 2021 | 10 | 0.230 |
Why?
|
Lung Injury | 1 | 2024 | 1 | 0.230 |
Why?
|
Orthomyxoviridae Infections | 1 | 2024 | 4 | 0.230 |
Why?
|
Herpesviridae | 1 | 2023 | 3 | 0.230 |
Why?
|
Cytomegalovirus | 1 | 2023 | 12 | 0.220 |
Why?
|
Tuberculosis, Multidrug-Resistant | 1 | 2022 | 1 | 0.210 |
Why?
|
Tuberculosis | 1 | 2022 | 5 | 0.210 |
Why?
|
Inflammation | 2 | 2020 | 59 | 0.200 |
Why?
|
Antiviral Agents | 2 | 2023 | 16 | 0.200 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 1 | 2021 | 6 | 0.190 |
Why?
|
Staphylococcal Infections | 1 | 2021 | 8 | 0.190 |
Why?
|
Pyrazines | 1 | 2021 | 1 | 0.190 |
Why?
|
Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2021 | 2 | 0.190 |
Why?
|
Methanol | 1 | 2021 | 5 | 0.190 |
Why?
|
Butylated Hydroxyanisole | 1 | 2021 | 1 | 0.190 |
Why?
|
Food Additives | 1 | 2021 | 1 | 0.190 |
Why?
|
Systemic Inflammatory Response Syndrome | 1 | 2021 | 3 | 0.190 |
Why?
|
Plants | 1 | 2021 | 25 | 0.190 |
Why?
|
Carbon | 1 | 2021 | 18 | 0.190 |
Why?
|
Fibroblasts | 1 | 2021 | 16 | 0.190 |
Why?
|
Cyclooxygenase 2 Inhibitors | 1 | 2021 | 6 | 0.190 |
Why?
|
Optical Imaging | 1 | 2021 | 17 | 0.190 |
Why?
|
Protein Domains | 1 | 2021 | 17 | 0.180 |
Why?
|
Apoptosis | 1 | 2021 | 55 | 0.180 |
Why?
|
Biocompatible Materials | 1 | 2021 | 23 | 0.180 |
Why?
|
Phenols | 1 | 2020 | 14 | 0.180 |
Why?
|
Purines | 1 | 2019 | 5 | 0.170 |
Why?
|
Biological Transport | 1 | 2019 | 18 | 0.170 |
Why?
|
Nucleotides | 1 | 2019 | 16 | 0.170 |
Why?
|
Activin Receptors, Type I | 1 | 2018 | 1 | 0.160 |
Why?
|
Pyrimidines | 1 | 2018 | 6 | 0.160 |
Why?
|
Sulfonamides | 1 | 2018 | 8 | 0.160 |
Why?
|
Pyridazines | 2 | 2015 | 3 | 0.160 |
Why?
|
Phthalazines | 1 | 2017 | 1 | 0.150 |
Why?
|
Francisella tularensis | 1 | 2017 | 2 | 0.150 |
Why?
|
Patents as Topic | 1 | 2017 | 2 | 0.140 |
Why?
|
Graft Rejection | 1 | 2017 | 4 | 0.140 |
Why?
|
Carbon-13 Magnetic Resonance Spectroscopy | 1 | 2016 | 1 | 0.140 |
Why?
|
Proton Magnetic Resonance Spectroscopy | 1 | 2016 | 3 | 0.140 |
Why?
|
K562 Cells | 1 | 2016 | 10 | 0.140 |
Why?
|
Mass Spectrometry | 1 | 2016 | 23 | 0.140 |
Why?
|
Mice, Inbred C57BL | 3 | 2024 | 195 | 0.130 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2015 | 14 | 0.130 |
Why?
|
Nod1 Signaling Adaptor Protein | 1 | 2015 | 1 | 0.130 |
Why?
|
Adenocarcinoma | 1 | 2015 | 10 | 0.130 |
Why?
|
Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 | 1 | 2015 | 1 | 0.130 |
Why?
|
Structural Homology, Protein | 1 | 2015 | 6 | 0.120 |
Why?
|
Lung Neoplasms | 1 | 2015 | 27 | 0.120 |
Why?
|
Mutant Proteins | 1 | 2015 | 5 | 0.120 |
Why?
|
Excitatory Amino Acid Transporter 2 | 1 | 2015 | 1 | 0.120 |
Why?
|
Cyclization | 1 | 2015 | 4 | 0.120 |
Why?
|
Amino Acid Substitution | 1 | 2015 | 17 | 0.120 |
Why?
|
Alkaloids | 1 | 2015 | 8 | 0.120 |
Why?
|
Nuclear Magnetic Resonance, Biomolecular | 1 | 2015 | 8 | 0.120 |
Why?
|
High-Throughput Screening Assays | 1 | 2015 | 12 | 0.120 |
Why?
|
Microbial Sensitivity Tests | 3 | 2022 | 92 | 0.120 |
Why?
|
Peptides | 1 | 2015 | 51 | 0.120 |
Why?
|
Anti-Bacterial Agents | 1 | 2017 | 166 | 0.120 |
Why?
|
Porphyrins | 1 | 2015 | 7 | 0.120 |
Why?
|
In Vitro Techniques | 1 | 2014 | 15 | 0.120 |
Why?
|
Palladium | 1 | 2015 | 16 | 0.120 |
Why?
|
Computer Simulation | 1 | 2015 | 180 | 0.110 |
Why?
|
Parkinson Disease | 1 | 2015 | 89 | 0.110 |
Why?
|
Alzheimer Disease | 1 | 2015 | 85 | 0.110 |
Why?
|
Mice, Transgenic | 2 | 2021 | 50 | 0.080 |
Why?
|
Female | 3 | 2024 | 2752 | 0.080 |
Why?
|
Molecular Sequence Data | 2 | 2015 | 50 | 0.060 |
Why?
|
Amino Acid Sequence | 2 | 2015 | 54 | 0.060 |
Why?
|
Bacillus anthracis | 1 | 2025 | 1 | 0.060 |
Why?
|
Cells, Cultured | 2 | 2015 | 134 | 0.060 |
Why?
|
Alveolar Epithelial Cells | 1 | 2024 | 3 | 0.060 |
Why?
|
Influenza A virus | 1 | 2024 | 3 | 0.060 |
Why?
|
Bacterial Proteins | 1 | 2025 | 55 | 0.060 |
Why?
|
Acrylamides | 1 | 2023 | 3 | 0.060 |
Why?
|
Virus Replication | 1 | 2023 | 2 | 0.060 |
Why?
|
Simplexvirus | 1 | 2023 | 5 | 0.060 |
Why?
|
Cell Nucleus | 1 | 2023 | 13 | 0.060 |
Why?
|
Coenzyme A | 1 | 2022 | 1 | 0.050 |
Why?
|
Phenylalanine | 1 | 2022 | 2 | 0.050 |
Why?
|
Biosynthetic Pathways | 1 | 2022 | 3 | 0.050 |
Why?
|
Inosine | 1 | 2021 | 1 | 0.050 |
Why?
|
Proteolysis | 1 | 2021 | 7 | 0.050 |
Why?
|
Staphylococcus aureus | 1 | 2021 | 20 | 0.050 |
Why?
|
HT29 Cells | 1 | 2021 | 5 | 0.050 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2021 | 14 | 0.050 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2021 | 12 | 0.050 |
Why?
|
Antioxidants | 1 | 2021 | 24 | 0.050 |
Why?
|
RAW 264.7 Cells | 1 | 2021 | 6 | 0.050 |
Why?
|
Materials Testing | 1 | 2021 | 19 | 0.050 |
Why?
|
HeLa Cells | 1 | 2021 | 18 | 0.050 |
Why?
|
Particle Size | 1 | 2021 | 43 | 0.050 |
Why?
|
Mutation | 1 | 2021 | 135 | 0.040 |
Why?
|
Tetrahydrofolate Dehydrogenase | 1 | 2019 | 1 | 0.040 |
Why?
|
Thymidylate Synthase | 1 | 2019 | 1 | 0.040 |
Why?
|
Multienzyme Complexes | 1 | 2019 | 4 | 0.040 |
Why?
|
Inhibitor of Apoptosis Proteins | 1 | 2018 | 1 | 0.040 |
Why?
|
X-Linked Inhibitor of Apoptosis Protein | 1 | 2018 | 1 | 0.040 |
Why?
|
Protein Conformation | 1 | 2018 | 45 | 0.040 |
Why?
|
Electron Transport Complex I | 1 | 2017 | 1 | 0.040 |
Why?
|
Tularemia | 1 | 2017 | 2 | 0.040 |
Why?
|
Cell Line | 1 | 2017 | 82 | 0.040 |
Why?
|
NAD | 1 | 2015 | 4 | 0.030 |
Why?
|
Sf9 Cells | 1 | 2015 | 1 | 0.030 |
Why?
|
Ubiquitination | 1 | 2015 | 7 | 0.030 |
Why?
|
Imidazoles | 1 | 2015 | 15 | 0.030 |
Why?
|
Protein Structure, Secondary | 1 | 2015 | 25 | 0.030 |
Why?
|
Plaque, Amyloid | 1 | 2015 | 8 | 0.030 |
Why?
|
Male | 1 | 2024 | 2704 | 0.030 |
Why?
|
Amyloid beta-Peptides | 1 | 2015 | 18 | 0.030 |
Why?
|
Neurons | 1 | 2015 | 131 | 0.030 |
Why?
|
Cognition | 1 | 2015 | 169 | 0.030 |
Why?
|